1. Search Result
Search Result
Results for "

Sunitinib Metabolite

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Isotope-Labeled Compounds

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-10873
    N-Desethyl Sunitinib
    5+ Cited Publications

    SU-12662

    Drug Metabolite Cancer
    N-Desethyl Sunitinib (SU-12662) is a metabolite of Sunitinib (HY-10255A). N-Desethyl Sunitinib serves as a good transport substrate for human ABCB1, ABCG2 and murine ABCG2 .
    N-Desethyl Sunitinib
  • HY-10873S

    Isotope-Labeled Compounds Drug Metabolite Cancer
    N-Desethyl Sunitinib-d5 is the deuterium labeled N-Desethyl Sunitinib. N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively .
    N-Desethyl Sunitinib-d5
  • HY-138813

    SU-12662 hydrochloride

    Drug Metabolite Cancer
    N-Desethyl Sunitinib (SU-12662) (hydrochloride) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively .
    N-Desethyl Sunitinib hydrochloride
  • HY-W754546

    Drug Metabolite Cancer
    2-Formyl sunitinib (1-CHO) is a metabolite of tyrosine kinase inhibitor Sunitinib (HY-10255A). 2-Formyl sunitinib can be used for the research of cancer .
    2-Formyl sunitinib
  • HY-117253

    Drug Metabolite Cancer
    PHA-782584 is a metabolite of sunitinib. Sunitinib is an oral multitargeted tyrosine kinase inhibitor with antitumor activities .
    PHA-782584
  • HY-10873S2

    SU-12662-d5 hydrochloride

    Isotope-Labeled Compounds Drug Metabolite Cancer
    N-Desethyl Sunitinib-d5 (hydrochloride) is a deuterated labeled N-Desethyl Sunitinib . N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively .
    N-Desethyl Sunitinib-d5 hydrochloride
  • HY-W591818

    Drug Derivative Cancer
    Sunitinib carboxylic acid is a carboxylic acid metabolite of Sunitinib (HY-10255A). Sunitinib is a multi-target tyrosine kinase inhibitor, mainly used to inhibit malignant tumors such as gastrointestinal stromal tumors, renal cell carcinoma, and pancreatic neuroendocrine tumors .
    Sunitinib carboxylic acid
  • HY-10873R

    SU-12662 (Standard)

    Reference Standards Drug Metabolite Cancer
    N-Desethyl Sunitinib (Standard) is the analytical standard of N-Desethyl Sunitinib. This product is intended for research and analytical applications. N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively[1].
    N-Desethyl Sunitinib (Standard)
  • HY-138813R

    SU-12662 hydrochloride (Standard)

    Reference Standards Drug Metabolite Cancer
    Glycochenodeoxycholic acid sodium salt (Standard) is the analytical standard of Glycochenodeoxycholic acid sodium salt. This product is intended for research and analytical applications. Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .
    N-Desethyl Sunitinib hydrochloride (Standard)
  • HY-138813A

    (E/Z)-SU-12662 hydrochloride

    Phosphodiesterase (PDE) Cancer
    (E/Z)-N-Desethylsunitinib hydrochloride ((E/Z)-SU-12662 hydrochloride) is a compound with potential anti-tumor activity that inhibits VEGF-R2 and PDGF-Rβ tyrosine kinases. (E/Z)-N-Desethylsunitinib hydrochloride is the main active metabolite of sunitinib and has the ability to competitively inhibit ATP .
    (E/Z)-N-Desethylsunitinib hydrochloride

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

 

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

 

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: